HOME >> MEDICINE >> NEWS
Ace inhibitors could slow muscle decline

Angiotensin-converting enzyme (ACE) inhibitors, a class of drugs used to lower blood pressure, could also be protective against the decline in muscle strength in elderly women suggest authors of a study in this weeks issue of THE LANCET.

ACE inhibitors are known to prevent the decline in physical function in patients with congestive heart failure (CHF). Graziano Onder and colleagues from Wake Forest University, USA, investigated whether ACE inhibitors could also prevent reduction in physical performance and in muscle strength in elderly women who did not have CHF.

3-year rates of decline in the strength of the extensor muscle around the knee and walking-speed reduction was assessed in 641 women with hypertension. The participants (whose average age was 79 years) had taken part in the Womens Health and Aging Study, and were stratified into four groups depending on their type and duration of antihypertensive drug treatment. 61 had used ACE inhibitors continuously, 133 intermittently, 301 had used other antihypertensive drugs either continuously or intermittently and 146 had never used antihypertensive drugs.

Women who were continuous users of ACE inhibitors had a lower average 3-year decline in muscle strength of 1 kg compared with a decline of 3.7 kg in continuous/intermittent users of other antihypertensive drugs. Women who had never used antihypertensive drugs had an average decline in muscle strength of 3.9 kg. Continuous ACE inhibitor users had a substantially smaller reduction in 3-year walking speed (1.7 cm per second) compared with intermittent users of ACE inhibitors (13.6 cm per second). The 3-year walking-speed reduction was substantially greater in intermittent users of other antihypertensive drugs (15.7 cm per second) and for women who did not use antihypertensive drugs at all (17.9 cm per second reduction in speed).

Graziano Onder comments: Our results suggest that ACE inhibitor treatment could decrease long-term decline
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
14-Mar-2002


Page: 1 2

Related medicine news :

1. COX-2 inhibitors associated with blood pressure elevation
2. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
3. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk
4. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
5. Breast cancer may be uniquely sensitive to inhibitors of PI3K pathway
6. Aromatase inhibitors should be first-line treatment for certain type of breast cancer
7. Researchers debate recreational use of PDE-5 inhibitors
8. ACE inhibitors not needed for many heart disease patients, according to new study
9. HIV-1 protease inhibitors: Effective against malaria?
10. Mechanism found that protects aggressive melanoma from angiogenesis inhibitors
11. Lupus discovery may pave way to better-designed COX-2 inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Ace inhibitors could slow muscle decline

(Date:6/19/2013)... The former internist for the St. Louis ... serves as director of prevention and wellness at St. ... personal encounter with a metabolic syndrome diagnosis and a ... , that he credits with sparking the paradigm-shift that ... practice. , “The average medical student gets 30 minutes ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... The US Food and Drug Administration (FDA) announced ... breast implant, Mentor Worldwide’s MemoryShape™. , The FDA approved Sientra/Silimed ... FDA announced the approval of the MemoryShape™ implant on June ... in women 22 years old or older and in ... FDA’s approval comes after six years of data from 955 ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: